Evidence map›Paper›PMID 21986942›Full record

ArticleOncogene2012

A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors.

E C Piccione, T J Lieu, C F Gentile, T R Williams, A J Connolly, A K Godwin, A C Koong, A J Wong

Abstract read
In one paragraph

Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Receptor tyrosine kinases in the nucleus.Cold Spring Harbor perspectives in biology · 2013
    Review
  12. Article
  13. ENTPD5-mediated modulation of ATP results in altered metabolism and decreased survival in gliomablastoma multiforme.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

E C PiccioneDepartment of Neurosurgery and Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
T J Lieu
C F Gentile
T R Williams
A J Connolly
A K Godwin
A C Koong
A J Wong
Stanford University · USUniversity of Kansas Medical Center · US

Funding

Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DALY, MARY BERYL, REBBECK, TIMOTHY R · 1999 to 2013
$33.6M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORSR01CA069495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WONG, ALBERT J. · 1996 to 2009
$2.8M
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian CancerR01CA140323 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K. · 2010 to 2014
$2.1M
The Role of JNK in Glial Tumor PathogenesisR01CA096539 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WONG, ALBERT J. · 2002 to 2006
$1.6M
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human GliomasR01CA124832 · NCI · STANFORD UNIVERSITY · PI WONG, ALBERT J. · 2007 to 2011
$1.5M
Characterization of a novel EGFR variant in GlioblastomaF31NS056581 · NINDS · STANFORD UNIVERSITY · PI GRIFFIN, EMILY PICCIONE · 2006 to 2009
$192k
NCI NIH HHS P50 CA083638NCI NIH HHS R01 CA069495NCI NIH HHS R01 CA096539NCI NIH HHS R01 CA124832NCI NIH HHS R01 CA140323NCI NIH HHS R01 CA69495NCI NIH HHS T32 CA009302NINDS NIH HHS F31 NS056581
6 · The paper itself

Abstract

The epidermal growth factor receptor (EGFR) is essential to multiple physiological and neoplastic processes via signaling by its tyrosine kinase domain and subsequent activation of transcription factors. EGFR overexpression and alteration, including point mutations and structural variants, contribute to oncogenesis in many tumor types. In this study, we identified an in-frame splice variant of the EGFR called mini-LEEK (mLEEK) that is more broadly expressed than the EGFR and is overexpressed in several cancers. Unlike previously characterized EGFR variants, mLEEK lacks the extracytoplasmic, transmembrane and tyrosine kinase domains. mLEEK localizes in the nucleus and functions as a transcription factor to regulate target genes involved in the cellular response to endoplasmic reticulum (ER) stress, including the master regulator of the unfolded protein response (UPR) pathways, molecular chaperone GRP78/Bip. We demonstrated that mLEEK regulates GRP78 transcription through direct interaction with a cis-regulatory element within the gene promoter. Several UPR pathways were interrogated and mLEEK expression was found to attenuate the induction of all pathways upon ER stress. Conversely, knockdown of mLEEK resulted in caspase-mediated cell death and sensitization to ER stress. These findings indicate that mLEEK levels determine cellular responses to unfavorable conditions that cause ER stress. This information, along with the overexpression of mLEEK in tumors, suggests unique strategies for therapeutic intervention. Furthermore, the identification of mLEEK expands the known mechanisms by which the EGFR gene contributes to oncogenesis and represents the first link between two previously disparate areas in cancer cell biology: EGFR signaling and the UPR.

Indexed as

Gene Expression Regulation, NeoplasticTranscriptional ActivationTranscription, GeneticAdenocarcinomaCell Line, TumorCell NucleusEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressErbB ReceptorsFemaleHeat-Shock ProteinsHumansLungLung NeoplasmsMelanomaNeoplasmsEGFR protein, humanEndoplasmic Reticulum Chaperone BiPErbB ReceptorsHeat-Shock ProteinsHSPA5 protein, humanProtein Isoforms

Identifiers

PMID21986942
PMCPMC3368095
OpenAlexW2010179828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.